Ovid has successfully completed multiple clinical stage studies in rare neurological disorders. We continue to execute on our strategy to build a robust pipeline of first-in-class compounds and programs by discovering, in-licensing and collaborating with leading biopharmaceutical companies and academic institutions.
Our commitment to clinical study data transparency
Clinical data transparency is important to Ovid, especially as we work so closely with patient communities. We are committed to ensuring that our research practices are transparent, responsible and fully compliant with applicable laws, regulations and guidelines, including the PhRMA/EFPIA and IFPMA Principles for Responsible Clinical Trial Data Sharing.
At Ovid, we know it takes a committed team to get breakthrough treatments into the hands of those who truly need them. Collaboration is critical in bringing impactful medicines to those who need it most. We seek like-minded potential partners driven to produce clinically impactful work for rare disease individuals and families. If you are a researcher, represent an academic medical center interested in collaborating or are interested in submitting an investigator-initiated trial (ITT), please contact us at clinical@ovidrx.com.